Your browser doesn't support javascript.
loading
A novel bioassay to assess bioactivity of PEG-rhGH using Nb2-11 cells / 药学学报
Acta Pharmaceutica Sinica ; (12): 773-778, 2023.
Article in Zh | WPRIM | ID: wpr-965638
Responsible library: WPRO
ABSTRACT
In this study, we established a novel bioassay to determine the activity of polyethylene glycolated recombinant human growth hormone (PEG-rhGH) using Nb2-11 cells. We performed experimental condition optimization and methodological verification, and then detected the relative potency of PEG-rhGH products using this method. We demonstrated that the bioactivity of PEG-rhGH in promoting Nb2-11 cell proliferation displays a dose-response relationship, which conformed to the four-parameter model. Using PEG-rhGH reference as a control, we analyzed the relative potency of six batches of PEG-rhGH products, as well as linearity, regression and parallelism of the obtained curves. The relative potency of six batches of PEG-rhGH products was 95% to 105%. These results implied that the new bioassay established may be employed in quality control of PEG-rhGH products.
Key words
Full text: 1 Index: WPRIM Language: Zh Journal: Acta Pharmaceutica Sinica Year: 2023 Type: Article
Full text: 1 Index: WPRIM Language: Zh Journal: Acta Pharmaceutica Sinica Year: 2023 Type: Article